CervoMed (CervoMed) Cash And Cash Equivalents : $7.79 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is CervoMed Cash And Cash Equivalents?

CervoMed's quarterly cash and cash equivalents declined from Jun. 2023 ($15.00 Mil) to Sep. 2023 ($10.43 Mil) but then stayed the same from Sep. 2023 ($10.43 Mil) to Dec. 2023 ($7.79 Mil).

CervoMed's annual cash and cash equivalents declined from Dec. 2021 ($37.31 Mil) to Dec. 2022 ($4.09 Mil) but then increased from Dec. 2022 ($4.09 Mil) to Dec. 2023 ($7.79 Mil).

CervoMed Cash And Cash Equivalents Historical Data

The historical data trend for CervoMed's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CervoMed Cash And Cash Equivalents Chart

CervoMed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

14.18

18.52

37.31

4.09

7.79

CervoMed Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															4.09	14.65	15.00	10.43	7.79

CervoMed Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

CervoMed (NAS:CRVO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

CervoMed Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of CervoMed's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

CervoMed (CervoMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (NAS:CRVO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Park Plaza, Suite 424, Boston, MA, USA, 02216

Website

https://www.diffusionpharma.com

CervoMed Inc Formerly Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Geographically business activity of the firm functions through the region of the United States.

Executives

Frank Zavrl	director	C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Sylvie Gregoire	director, 10 percent owner	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
John William Tanner	officer: Chief Financial Officer	C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116
Kelly Blackburn	officer: VP, Clinical Development	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marwan Sabbagh	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John J Alam	director, 10 percent owner, officer: CEO and President	130 WAVERLY STREET, CAMBRIDGE MA 02139
Jeffrey V. Poulton	director	300 THIRD STREET, CAMBRIDGE MA 02142
Jill Davidson	director	300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902
Raven Jaeger	officer: Chief Regulatory Officer	300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902
Eric Francois	director	C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Diana M Lanchoney	director	1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902
William Robert Elder	officer: GC & Secretary	1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Cobuzzi Robert Joseph Jr.	director	C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Christopher D Galloway	officer: Chief Medical Officer	1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Jane H Hollingsworth	director	DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902